Christian Chabannon
Overview
Explore the profile of Christian Chabannon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
213
Citations
5512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Franceschi L, Locatelli F, Rees D, Chabannon C, Dalle J, Rivella S, et al.
Hemasphere
. 2025 Mar;
9(3):e70089.
PMID: 40084235
Sickle cell disease (SCD) remains associated with reduced life expectancy and poor quality of life despite improvements observed in the last decades mostly related to comprehensive care, use of hydroxycarbamide,...
2.
Pagliuca S, Malard F, Mooyaart J, Daskalakis M, Gabellier L, Yakoub-Agha I, et al.
Blood Rev
. 2025 Feb;
:101272.
PMID: 39986989
Immune monitoring of cell therapies is a complex and evolving topic, particularly in the rapid expanding field of chimeric antigen receptor T (CAR-T) cell applications. Defining essential, recommended, and optional...
3.
Boyer O, Bensoussan D, Bonig H, Chabannon C, Clemenceau B, Cuffel A, et al.
Bone Marrow Transplant
. 2025 Jan;
PMID: 39863732
The accessibility of CAR-T cells in centralized production models faces significant challenges, primarily stemming from logistical complexities and prohibitive costs. However, European Regulation EC No. 1394/2007 introduced a pivotal provision...
4.
Novak U, Mooyaart J, Daskalakis M, Scheid C, Gabellier L, Yakoub-Agha I, et al.
Bone Marrow Transplant
. 2024 Aug;
59(11):1631-1634.
PMID: 39192081
No abstract available.
5.
Chabannon C, Ruggeri A, Montoto S, van Biezen A, van der Werf S, Markslag A, et al.
Best Pract Res Clin Haematol
. 2024 Aug;
37(2):101557.
PMID: 39098799
The European society for Blood and Marrow Transplantation (EBMT) has a long-standing interest in the evaluation of hematopoietic cell transplantation. More than three decades ago, its members established a continental...
6.
Chabannon C, Visentin S, Granata A, Thuret I
Transfus Apher Sci
. 2024 Apr;
63(3):103926.
PMID: 38670856
No abstract available.
7.
Donor genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight
Schetelig J, Baldauf H, Heidenreich F, Hoogenboom J, Spellman S, Kulagin A, et al.
Front Immunol
. 2024 Apr;
15:1350470.
PMID: 38629074
Optimizing natural killer (NK) cell alloreactivity could further improve outcome after allogeneic hematopoietic cell transplantation (alloHCT). The donor's Killer-cell Immunoglobulin-like Receptor (KIR) genotype may provide important information in this regard....
8.
Chabannon C, Benakli M, Alexandrova K, Coze C, Dalle J, Giraud C, et al.
Bull Cancer
. 2024 Mar;
112(1S):S125-S134.
PMID: 38480055
Practice of pediatric aphereses - in particular when caring for low-weight children - differs from the practice of adult aphereses, since pediatric aphereses represent low numbers of procedures, which has...
9.
Sanchez-Guijo F, Vives J, Ruggeri A, Chabannon C, Corbacioglu S, Dolstra H, et al.
Cytotherapy
. 2024 Feb;
26(7):681-685.
PMID: 38416085
Cell and gene therapy poses evolving challenges. The current article summarizes the discussions held by European Regional Committee of the International Society for Cell & Gene Therapy and the European...
10.
Harbi S, Brac de la Perriere L, Bouchacourt B, Garciaz S, Pagliardini T, Calmels B, et al.
Bone Marrow Transplant
. 2023 Nov;
59(1):101-106.
PMID: 37923831
Haploidentical stem cell transplantation (Haplo-SCT) using non-myeloablative conditioning regimen (NMAC) has extended the feasibility of allogeneic transplantation, notably in older patients. However, there is few data specifically focusing on patients...